Reality Check

MMIT Reality Check on ADHD (Oct 2019)

October 25, 2019

According to our recent payer coverage analysis for attention deficit hyperactivity disorder (ADHD) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for attention deficit hyperactivity disorder (ADHD) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for ADHD treatments shows that under the pharmacy benefit, more than 45% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In April 2019, the FDA permitted marketing of the first medical device, called the Monarch external Trigeminal Nerve Stimulation System, to treat ADHD. It is indicated for patients ages 7 to 12 years old who are not currently taking prescription ADHD medication.

MMIT Reality Check on Hepatocelluar Carcinoma (Oct 2019)

October 18, 2019

According to our recent payer coverage analysis for hepatocelluar carcinoma treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for hepatocelluar carcinoma treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for hepatocelluar carcinoma treatments shows that under the pharmacy benefit, almost 55% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In May 2019, the FDA expanded the label of Cyramza (ramucirumab) to include the treatment of hepatocellular carcinoma in people with an alpha fetoprotein (AFP) of >400 ng/mL who previously were treated with Nexavar (sorafenib).

MMIT Reality Check on Psoriasis (Oct 2019)

October 11, 2019

According to our recent payer coverage analysis for psoriasis (PsO) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for psoriasis (PsO) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for psoriasis treatments shows that under the pharmacy benefit, almost 74% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In July 2019, the FDA approved Samsung Bioepis Co., Ltd.’s Hadlima (adalimumab-bwwd) for the treatment of plaque psoriasis, rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease and ulcerative colitis.

MMIT Reality Check on IBS-C (Oct 2019)

October 4, 2019

According to our recent payer coverage analysis for irritable bowel syndrome with constipation (IBS-C) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for irritable bowel syndrome with constipation (IBS-C) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for IBS-C treatments shows that under the pharmacy benefit, more than 42% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In September 2019, the FDA approved Ardelyx, Inc.’s Ibsrela (tenapanor) for the treatment of IBS-C in adults.

MMIT Reality Check on Soft Tissue Sarcoma (Sep 2019)

September 27, 2019

According to our recent payer coverage analysis for soft tissue sarcoma treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for soft tissue sarcoma treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for soft tissue sarcoma treatments shows that under the pharmacy benefit, about 60% and 70% of the lives under commercial and Medicare formularies are covered with utilization management restrictions, respectively.

Trends: In April 2019, Eli Lilly and Co. said it will withdraw advanced soft tissue sarcoma drug Lartruvo (olaratumab) from the market. The move follows the failure of a Phase III trial in which the therapy did not improve patient survival .

MMIT Reality Check on Immune Thrombocytopenic Purpura (Sep 2019)

September 20, 2019

According to our recent payer coverage analysis for immune thrombocytopenic purpura treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for immune thrombocytopenic purpura treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for immune thrombocytopenic purpura treatments shows that under the pharmacy benefit, about 63% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In June 2019, the FDA gave an additional indication to Doptelet (avatrombopag) for the treatment of thrombocytopenia who have had an insufficient response to prior treatment.